Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,146.1
-34.9 (-1.10%)

 

  • STI Straits Times Index
    3,146.1
    -34.9 (-1.10%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,490.4
    -40.8 (-2.66%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,872.8
    -436.0 (-1.60%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,031.2
    -8.4 (-0.28%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,386.7
    -92.4 (-0.39%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,799.5
    -82.7 (-1.41%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 888.0M
  • Value: 1,070.3M
  • Rise: 46
  • Fall: 306
  • Unch: 462

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
AusGroup^0.044-0.004
Rex Intl0.181-0.012
Medtecs Intl0.097-
Golden Agri-Res0.205-0.010
YZJ Shipbldg SGD1.000-0.040
ThaiBev0.820-0.025
Singtel3.120+0.020
Broadway Ind^0.077-0.023
OEL0.026-0.002
Kep Infra Tr0.535-0.010

World Indices

World Indices
Name Last Change
Nasdaq 9,576.6 -174.4
HSI 26,854.8 -454.0
HSCEI 10,583.0 -207.9
Jakarta 5,801.7 -80.6
Nikkei 225 23,386.7 -92.4
SSE Comp 3,031.2 -8.4
Shanghai A 3,176.5 -8.8
Shanghai B 244.5 -0.4
KOSPI 2,079.0 -83.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

LEAP THERAPEUTICS INC LEAP THERAPEUTICS
Updated on 21 Feb 2020 (End of trading day)
Last (USD): 2.600 Change: -0.110 High: 2.730 Remarks: -
Change (%): -4.06 Low: 2.580
Open 2.690 Yesterday's Close 2.71
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 455,896 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.95632 Trailing EPS (USD) e -0.98298 NAV (USD) b 0.2299
PE a - Trailing PE f - Price / NAV b 11.3093
Dividend (USD) d - Cash In Hand (USD) g 0.4157 Issued & Paid-up Shares c 24,194,900
Dividend Yield (%) d - Price / Cash In Hand g 6.255 Treasury Shares h -
Beta - 75 Daysi 1.326 R-Squared - 75 Days(%)i 0.06 Market Cap (M) 62.907
Beta - 500 Daysi 0.326 R-Squared - 500 Days (%)i 0.36 Enterprise Value (M) 54.063
Piotroski F Score 1 Exchange Code LPTX Par Value ( $ ) n.a.
52 Weeks Volatility (%) 114.78 Free Float (%) 59.9
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 15 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 25 Jan 2017.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference LEAP THERAPEUTICS INC NASDAQ 62.907 - - 11.3093 -
Industry Biotechnology NASDAQ 2,489.295 316.829 197.255 6.0515 0.730
Local Peer AMGEN INC NASDAQ 131,403.102 15.654 16.756 13.5845 2.530
Local Peer GILEAD SCIENCES INC NASDAQ 88,240.200 16.176 16.383 3.8958 3.313
Local Peer VERTEX PHARMACEUTICAL NASDAQ 63,855.362 30.460 54.261 10.4935 -
Local Peer BIOGEN INC NASDAQ 58,609.089 13.228 9.953 4.3924 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 44,354.551 18.145 20.963 3.9996 -
Local Peer ILLUMINA INC NASDAQ 43,503.180 52.667 43.416 9.4305 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 22,835.299 294.265 9.498 2.0259 -
Local Peer SEATTLE GENETICS INC NASDAQ 20,154.420 - - 10.7416 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 17,720.698 - 57.097 6.4113 -
Local Peer INCYTE CORPORATION NASDAQ 17,535.011 160.147 39.236 6.7484 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 17,093.115 - - 5.5598 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 14,751.882 - - 10.2537 -
Other Local Peers EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), EXELIXIS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ALKERMES PLC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), INSMED INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), ALECTOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), EPIZYME INC (NASDAQ), VIELA BIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), ARVINAS INC (NASDAQ), REGENXBIO INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CORTEXYME INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), MYRIAD GENETICS INC (NASDAQ), NEXTCURE INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), DERMIRA INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), IMMUNOGEN INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), PRECIGEN INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), RETROPHIN INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ARDELYX INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), COMPUGEN (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), XBIOTECH INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), NANTKWEST INC (NASDAQ), MACROGENICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), MERUS B V (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), AGENUS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), PROTHENA CORP PLC (NASDAQ), TRANSLATE BIO INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CUE BIOPHARMA INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), RECRO PHARMA INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), PERSONALIS INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), IVERIC BIO INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), KAMADA (NASDAQ), SERES THERAPEUTICS (NASDAQ), VBI VACCINES INC CDA (NASDAQ), GERON CORP (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NOVAVAX INC (NASDAQ), XOMA CORP (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), IMV INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), MEDICINOVA INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ATHERSYS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CHIASMA INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), VERASTEM INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CELYAD ADS EACH REPR 1 ORD (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), ARAVIVE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), AXCELLA HEALTH INC (NASDAQ), SAVARA INC (NASDAQ), OTONOMY INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CHIMERIX INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VERMILLION INC (NASDAQ), SYNLOGIC INC (NASDAQ), VACCINEX INC (NASDAQ), EQUILLIUM INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), ORGENESIS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), INMUNE BIO INC (NASDAQ), RESTORBIO INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), VAXART INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ZAFGEN INC (NASDAQ), CURIS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), TOCAGEN INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), BIOCARDIA INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), OCUGEN INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRECIPIO INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), SENESTECH INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ)
Global Peer CSL ASX 152,685.905 56.910 52.709 - 0.789
Global Peer AMGEN-T HKEx 589,807.000 8.965 9.598 7.8255 4.417
Global Peer AGILENT TECHNOLOGIES INC NYSE 26,437.034 83.661 34.603 5.4532 0.717
Global Peer WUXI BIO HKEx 148,129.957 198.323 155.044 15.2482 -
Global Peer SINO BIOPHARM HKEx 138,334.092 12.910 13.399 4.1197 0.665
Global Peer BEIGENE HKEx 99,464.306 - - 9.9241 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer GENSCRIPT BIO HKEx 31,999.780 192.438 - 9.0238 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 3,409.098 54.371 62.438 3.1319 -
Global Peer 3SBIO HKEx 25,399.700 16.790 20.437 2.5034 -
Other Global Peers ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), POLYNOVO LIMITED (ASX), FRONTAGE (HKEx), AVITA MEDICAL LTD (ASX), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD (ASX), VIVA BIOTECH (HKEx), KADMON HLDGS INC (NYSE), ARCUS BIOSCIENCES INC (NYSE), ASCENTAGE-B (HKEx), ASCLETIS-B (HKEx), SINOMAB BIO-B (HKEx), NANOVIRICIDES INC (NYSE American), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), PFENEX INC (NYSE American), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), BBI LIFE SCI (HKEx), NEXT SCIENCE LTD (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), CEL-SCI CORP (NYSE American), UNI-BIO GROUP (HKEx), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), IMMUTEP LTD (ASX), ENZO BIOCHEM INC (NYSE), IMUGENE LIMITED (ASX), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), CYNATA THERAPEUTICS LTD (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), CT ENTERPRISE (HKEx), BIOTRON (ASX), INVEX THERAPEUTICS LTD NPV (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), BIOSINO BIO-TEC (HKEx), HOLISTA COLLTECH LIMITED (ASX), MEMPHASYS LTD (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ORAGENICS INC (NYSE American), ANTEOTECH LIMITED (ASX), CCP TECHNOLOGIES LTD (ASX), IBIO INC (NYSE American), REGENT PACIFIC (HKEx), GENETIC TECHNOLOGIES (ASX), BIONOMICS LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), ACTINIUM PHARMACEUTICALS INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), RHINOMED LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), REGENEUS LTD (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American), ADALTA LTD (ASX), BENITEC BIOPHARMA LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), LEAF RESOURCES LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), FACTOR THERAPEUTICS LIMITED (ASX), CRYOSITE (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.450
+20.93 %
10 Days -+0.740
+39.78 %
20 Days -+0.770
+42.08 %
Medium Term Return 3 Months -+1.876
+259.12 %
6 Months -+1.120
+75.68 %
1 Year -+1.070
+69.93 %
Long Term Return 2 Years --3.840
-59.63 %
3 Years --4.470
-63.22 %
Annualised Return Annualised --
-28.36 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.573 - 3.180 Change From 1 Year Low +2.027 % Change From 1 Year Low (%) +353.91
Change From 1 Year High -0.580 % Change From 1 Year High (%) -18.24
2 Years Range 0.573 - 10.250 Change From 2 Years Low +2.027 % Change From 2 Years Low (%) +353.91
Change From 2 Years High -7.650 % Change From 2 Years High (%) -74.63
5 Years Range 0.573 - 10.250 Change From 5 Years Low +2.027 % Change From 5 Years Low (%) +353.91
Change From 5 Years High -7.650 % Change From 5 Years High (%) -74.63
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Feb 2020 2.690 2.730 2.580 2.600 455,896 -
20 Feb 2020 2.950 3.020 2.550 2.710 1,283,423 -
19 Feb 2020 2.340 3.180 2.324 2.900 4,036,295 -
18 Feb 2020 2.170 2.380 2.170 2.300 783,555 -
14 Feb 2020 2.020 2.220 2.020 2.150 270,865 -
13 Feb 2020 2.050 2.141 1.980 2.010 244,958 -
12 Feb 2020 2.150 2.240 2.030 2.040 318,558 -
11 Feb 2020 2.040 2.300 2.000 2.130 1,857,928 -
10 Feb 2020 1.780 1.920 1.760 1.860 260,884 -
07 Feb 2020 1.870 1.886 1.760 1.780 166,625 -
06 Feb 2020 1.920 1.930 1.860 1.890 147,896 -
05 Feb 2020 1.920 1.940 1.840 1.920 133,730 -
04 Feb 2020 1.840 1.924 1.820 1.870 130,004 -
03 Feb 2020 1.910 1.950 1.800 1.830 126,159 -
31 Jan 2020 1.820 1.940 1.820 1.910 327,613 -
30 Jan 2020 1.920 1.950 1.810 1.870 168,291 -
29 Jan 2020 1.750 1.950 1.750 1.910 344,741 -
28 Jan 2020 1.810 1.860 1.730 1.780 245,182 -
27 Jan 2020 1.820 1.999 1.760 1.830 398,838 -
24 Jan 2020 2.050 2.090 1.820 1.900 742,292 -
23 Jan 2020 2.000 2.460 1.850 2.000 6,211,278 -
22 Jan 2020 1.830 1.900 1.750 1.790 315,644 -
Summary
Current 2 Weeks
(07 Feb 2020 to 21 Feb 2020)
1.870 3.180 1.760 2.600 9,678,987 -
Previous 2 Weeks
(24 Jan 2020 to 06 Feb 2020)
2.050 3.180 1.760 1.890 2,764,746 -
4 Weeks from
(24 Dec 2019 to 23 Jan 2020)
0.960 3.180 0.960 2.000 33,155,052 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.